AR029600A1 - Un derivado del acido fenoxiacetico, una composicion farmaceutica que lo contiene y agente util para la prevencion de enfermedades, uso de un derivado del acido fenoxiacetico para la fabricacion de una composicion farmaceutica para los tratamientos de dichas enfermedades y el procedimiento de fabric - Google Patents

Un derivado del acido fenoxiacetico, una composicion farmaceutica que lo contiene y agente util para la prevencion de enfermedades, uso de un derivado del acido fenoxiacetico para la fabricacion de una composicion farmaceutica para los tratamientos de dichas enfermedades y el procedimiento de fabric

Info

Publication number
AR029600A1
AR029600A1 ARP990103315A ARP990103315A AR029600A1 AR 029600 A1 AR029600 A1 AR 029600A1 AR P990103315 A ARP990103315 A AR P990103315A AR P990103315 A ARP990103315 A AR P990103315A AR 029600 A1 AR029600 A1 AR 029600A1
Authority
AR
Argentina
Prior art keywords
group
lower alkyl
phenoxyacetic acid
pharmaceutical composition
acid derivative
Prior art date
Application number
ARP990103315A
Other languages
English (en)
Inventor
Nobuyuki Tanaka
Tetsuro Tamai
Akihito Hirabayashi
Hideyuki Muranaka
Masaaki Sato
Masuo Akahanae
Harunobu Mukaiyama
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of AR029600A1 publication Critical patent/AR029600A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Maintenance And Inspection Apparatuses For Elevators (AREA)

Abstract

Un derivado del ácido fenoxiacético representado por la formula general: 1 donde R1 representa un grupo hidroxi, un grupo alcoxi, inferior, un grupo aralcoxi, un grupo amino o un grupo mono- o di (alquil inferior ) amino; uno de R2 y R3 es un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo inferior, o un grupo alcoxi inferior, mientras que el otro es un átomo de hidrogeno; r4 representa un átomo de halogeno, un grupo alquilo inferior, un grupo halo (alquilo inferior), un grupo hidroxi, un grupo alcoxi inferior, un grupo aralcoxi, un grupo ciano, un grupo nitro, un grupo amino, un grupo mono- o di (alquil inferior) amino, un grupo carbamoílo, un grupo mono o di (alquil inferior) carbamoílo o un grupo representado por la formula : -NHCOR5 (donde R5 representa un átomo de hidrogeno o un grupo alquilo inferior; el átomo de carbono marcado con (R) representa un átomo de carbono en configuracion R y el átomo de carbono marcado con (S) representa un átomo de carbono en configuracion (S) y sus sales farmacéuticamente aceptables, que tienen excelentes efectos estimulantes de los beta 3 - adrenoceptores y que son utiles como agentes para la prevencion o el tratamiento de la obesidad, la hiperglicemia, las enfermedades causadas por hipermotilidad intestinal, polaquiuria, incontinencia urinaria o depresion, o las enfermedades causadas por cálculos biliares o hipermotilidad del tracto biliar.
ARP990103315A 1998-07-08 1999-07-07 Un derivado del acido fenoxiacetico, una composicion farmaceutica que lo contiene y agente util para la prevencion de enfermedades, uso de un derivado del acido fenoxiacetico para la fabricacion de una composicion farmaceutica para los tratamientos de dichas enfermedades y el procedimiento de fabric AR029600A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22850198 1998-07-08

Publications (1)

Publication Number Publication Date
AR029600A1 true AR029600A1 (es) 2003-07-10

Family

ID=16877446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103315A AR029600A1 (es) 1998-07-08 1999-07-07 Un derivado del acido fenoxiacetico, una composicion farmaceutica que lo contiene y agente util para la prevencion de enfermedades, uso de un derivado del acido fenoxiacetico para la fabricacion de una composicion farmaceutica para los tratamientos de dichas enfermedades y el procedimiento de fabric

Country Status (28)

Country Link
US (1) US6538152B1 (es)
EP (1) EP1095932B1 (es)
JP (2) JP4132010B2 (es)
KR (1) KR100516277B1 (es)
CN (1) CN1242983C (es)
AR (1) AR029600A1 (es)
AT (1) ATE267161T1 (es)
AU (1) AU771200B2 (es)
BR (1) BR9911871B1 (es)
CA (1) CA2336853C (es)
CO (1) CO5070574A1 (es)
CZ (1) CZ302727B6 (es)
DE (1) DE69917459T2 (es)
DK (1) DK1095932T3 (es)
ES (1) ES2221390T3 (es)
HK (1) HK1039480A1 (es)
HU (1) HUP0103008A3 (es)
IL (1) IL140498A (es)
MY (1) MY126489A (es)
NO (1) NO327770B1 (es)
NZ (1) NZ509203A (es)
PE (1) PE20000758A1 (es)
PL (1) PL197453B1 (es)
PT (1) PT1095932E (es)
SA (1) SA99200411B1 (es)
TW (1) TW432040B (es)
WO (1) WO2000002846A1 (es)
ZA (1) ZA200100135B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
EA006022B1 (ru) 2001-09-13 2005-08-25 Киссеи Фармасьютикал Ко., Лтд. Кристаллы производных гидроксинорэфедрина
UA79498C2 (en) * 2002-09-05 2007-06-25 Kissei Pharmaceutical Intermediates for preparation of phenoxy-acetic derivates and processes of their preparation
NZ539577A (en) 2002-11-07 2007-06-29 Astellas Pharma Inc Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PT1620085E (pt) * 2003-05-05 2008-08-07 Kissei Pharmaceutical Utilização de derivados de ácido fenoxiacético para tratamento de bexiga hiperactiva
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US20090247781A1 (en) 2004-10-26 2009-10-01 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
LT5282B (lt) 2005-02-28 2005-10-25 Kissei Pharmaceutical Co., Ltd. Tarpiniai junginiai fenoksiacto rūgšties darinių gamyboje ir jų panaudojimo būdas
US8003694B2 (en) 2005-04-26 2011-08-23 Kissei Pharmaceutical Co., Ltd. Crystal of hydroxynorephedrin derivative hydrochloride ¼ hydrate
CA2605337A1 (en) * 2005-04-26 2006-11-23 Kissei Pharmaceutical Co., Ltd. Crystal polymorph of hydroxynorephedrin derivative hydrochloride
AU2006285963A1 (en) * 2005-08-29 2007-03-08 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
JPWO2007083640A1 (ja) * 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6401871A (es) 1964-02-27 1965-08-30
ATE1994T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Aethanamin-derivate, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
GB8418472D0 (en) * 1984-07-19 1984-08-22 Beecham Group Plc Compounds
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
AU4320297A (en) * 1996-09-26 1998-04-17 Kissei Pharmaceutical Co. Ltd. 2-amino-1-(4-hydroxy-2-methylphenyl)propanol derivatives
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing

Also Published As

Publication number Publication date
CN1308603A (zh) 2001-08-15
CZ302727B6 (cs) 2011-09-29
BR9911871A (pt) 2001-03-27
DE69917459T2 (de) 2005-05-12
JP4871321B2 (ja) 2012-02-08
NZ509203A (en) 2003-03-28
EP1095932A4 (en) 2002-10-16
JP4132010B2 (ja) 2008-08-13
CO5070574A1 (es) 2001-08-28
HUP0103008A3 (en) 2002-12-28
PT1095932E (pt) 2004-09-30
SA99200411B1 (ar) 2006-09-09
TW432040B (en) 2001-05-01
EP1095932A1 (en) 2001-05-02
ZA200100135B (en) 2001-12-10
NO20010078D0 (no) 2001-01-05
PL197453B1 (pl) 2008-04-30
AU771200B2 (en) 2004-03-18
BR9911871B1 (pt) 2010-10-19
IL140498A0 (en) 2002-02-10
US6538152B1 (en) 2003-03-25
CZ200173A3 (cs) 2002-01-16
HK1039480A1 (en) 2002-04-26
ATE267161T1 (de) 2004-06-15
PL345730A1 (en) 2002-01-02
DK1095932T3 (da) 2004-09-20
KR20010071772A (ko) 2001-07-31
KR100516277B1 (ko) 2005-09-21
NO20010078L (no) 2001-03-08
CA2336853C (en) 2009-03-10
CN1242983C (zh) 2006-02-22
HUP0103008A2 (hu) 2001-12-28
WO2000002846A1 (en) 2000-01-20
NO327770B1 (no) 2009-09-21
CA2336853A1 (en) 2000-01-20
JP2008273965A (ja) 2008-11-13
MY126489A (en) 2006-10-31
IL140498A (en) 2004-06-20
ES2221390T3 (es) 2004-12-16
EP1095932B1 (en) 2004-05-19
AU4397399A (en) 2000-02-01
DE69917459D1 (de) 2004-06-24
PE20000758A1 (es) 2000-09-04

Similar Documents

Publication Publication Date Title
AR029600A1 (es) Un derivado del acido fenoxiacetico, una composicion farmaceutica que lo contiene y agente util para la prevencion de enfermedades, uso de un derivado del acido fenoxiacetico para la fabricacion de una composicion farmaceutica para los tratamientos de dichas enfermedades y el procedimiento de fabric
AR037069A2 (es) Un nuevo derivado de la quinolin-4-carboxamida, la n-(alfa-etilbencil)-3-hidroxi-2-fenilquinolin-4-carboxamida, una composicion farmaceutica que lo contiene y su uso para la fabricacion de medicamentos
DE60238255D1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
AR035320A1 (es) Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta
PE20030894A1 (es) Acridona como inhibidores de la enzima impdh
PA8432901A1 (es) Compuestos de piridilpirrol
AR048197A1 (es) Metodos para tratar la esquizofrenia y/o anomalias de glucorregulacion
PE20030607A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
PE55998A1 (es) Derivados 19-nor-pregneno substituidos
AR011409A1 (es) Derivados de 16-hidroxi-11-(fenil substituido)-estra-4,9-dieno, su utilizacion, un procedimiento para prepararlos, formulaciones farmaceuticasque comprenden a dichos derivados, y un compuesto utilizable como intermediario para prepararlos
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
BR0012610A (pt) Novo derivado de difenilpiperidina
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
AR017858A1 (es) Derivados de acido fenilaminoalquilcarboxilico utiles como estimulantes de los beta3-adrenoceptores, composicion farmaceutica, estimulante de losbeta3-adrenoceptores, usos en la fabricacion de medicamentos y procedimiento de fabricacion
UY27593A1 (es) Nuevos compuestos
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
AR036176A1 (es) Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado
ATE341319T1 (de) Esmolol-enthaltende zubereitungen
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
AR015761A1 (es) Un derivado del acido 2-metilpropionico,una composicion farmaceutica que lo incluye, uso de un derivado del acido 2-metilpropionico y un procedimiento parala fabricacion de una composicion farmaceutica para la prevencion o el tratamiento de enfermedades
AR032553A1 (es) Derivados de alfa-amino-n-hidroxi-acetamida.
AR032622A1 (es) Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos
BG105997A (en) Method of controlling weight gain associated with therapeutic drugs
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv

Legal Events

Date Code Title Description
FG Grant, registration